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Since the studies by Virchow (1) in 1847 and Anitschkow (2) 
in 1913, it has been known that high levels of blood choles- 
terol are related to atherosclerotic lesions compromising 
regional circulation to the heart, brain and other vital organs. 
Nevertheless, it is debatable whether elevated blood choles- 
terol is a sufficient cause of atherosclerosis or whether a 
local degeneration of the intima is a prerequisite for the 
cholesterol deposit. Fundamental questions that need to be 
addressed (3-8) are: Should blood cholesterol be reduced in 
the entire population? To what extent may such a program 
prevent, arrest or reverse progress of obstructive arterio- 
sclerotic lesions? How far should we go in recommending 
blood cholesterol screening, dietary changes and perhaps the 
use of lipid-lowering drugs in individuals with only slightly to 
moderately elevated cholesterol levels? 
In the last year the medical profession has become 
alarmed about the continuing statements on radio and tele- 
vision and in the daily newspapers and national magazines 
encouraging the public to be aware of their cholesterol 
levels. The large anticholesterol advertising campaign in- 
itiated by the National Cholesterol Education Program 
(NCEP) of the National Heart, Lung, and Blood Institute 
(NHLBI) encourages the public to “know your blood cho- 
lesterol and bring it down.” Even at a cholesterol level of 
around 200 mg/dl, the NCEP recommends anticholesterol 
dietary interventions. Considering the high prevalence of 
hypercholesterolemia in the population, especially at the low 
levels now called “abnormal” by the NCEP, it is not clear 
how the medical profession or our society could respond 
effectively to the surge of patients seeking advice. 
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Diet and Drugs 
Even the strictest cholesterol-lowering diet seldom low- 
ers the level of serum cholesterol by > 10% (6). Even if such 
strict dietary modifications were feasible and effective, they 
might deprive the body of essential micronutrients, espe- 
cially in children (9) and if practiced by the inexperienced. 
All cholesterol-lowering drugs have their way of interfer- 
ing with the cholesterol metabolism. For instance, one drug 
may block cholesterol absorption from the gastrointestinal 
tract or block the bile acid recycling process, thereby 
increasing cholesterol excretion through the bowel. Another 
drug may reduce cholesterol production in the liver. The 
metabolic pathways within the cells may also be blocked. 
Triparanol stopped the metabolic cycle at the desmosterol 
level. This toxic cholesterol precursor caused hepatitis, 
exfoliative skin disorders and blindness due to cataracts (10). 
The cholesterol-lowering agent clofibrate has been reported 
to be associated with an increased incidence of gastrointes- 
tinal cancer. Furthermore, clofibrate has been linked to an 
increased occurrence of gallbladder disease (11). Nicotinic 
acid, disregarding subjective discomfort such as flushing, 
has generally been considered a fairly safe drug. Neverthe- 
less, it may decrease glucose tolerance and increase uric 
acid, thereby sometimes precipitating diabetes and gout in 
sensitive patients. New cholesterol-reducing drugs such as 
Lovastatin, an HMG-COA reductase inhibitor, are promis- 
ing but still lack long-term safety data. It is known that 
Lovastatin increases hepatic enzymes in up to 2% of treated 
patients. Myalgia associated with markedly elevated serum 
creatine kinase levels (myositis) has been reported in 0.5% of 
those treated. Acute renal failure has been precipitated by 
severe rhabdomyolysis. Cataract has also been discussed as 
a possible side effect of this compound (12). There is little 
wonder that members of the medical profession are con- 
cerned with an uncritical widening of the indications for such 
anticholesterol drug regimens. So far we do not have a 
completely safe cholesterol-lowering drug. 
Some “Historical” Remarks 
The first recommendations to change the government 
standards of cholesterol levels and to start a national anti- 
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cholesterol campaign originated in the Consensus Confer- 
ence arranged by the NHLBI (13). The conclusion of the 
consensus report, released to an assembled world press in 
December 1984, was that the cholesterol levels of the nation 
should be reduced by dietary measures beginning in child- 
hood. This recommendation was not approved by all re- 
searchers. In his article entitled “The Consensus or Non- 
sensus Conference of Coronary Heart Disease,” Oliver (14) 
complained that the final statements from the meeting were 
biased. The coordinator of the National Cholesterol Educa- 
tion Program (15) claimed in a memorandum that The Lipid 
Research Clinic Coronary Primary Prevention Trials (LRC- 
CPPT) data “provided the first conclusive experimental 
evidence in man that lowering elevated blood cholesterol 
levels would reduce the risk of heart attack and deaths from 
heart attacks” and that they were the “capstone to a body of 
evidence accumulated from all phases of medical research 
and provided the impetus for the development of the Na- 
tional Cholesterol Education Program.” What was missing 
from the LRC-CPPT report and other similarly well con- 
ducted clinical trials was the fact that none of them showed 
any reduction in overall mortality! Thus, some world author- 
ities of the scientific community questioned the NHLBI 
recommendations (16-22). 
Ironically, surveys sponsored by the NHLBI in 1983 (15) 
revealed that 80% of practicing physicians believed in the 
control of hypertension and smoking as a means of prevent- 
ing coronary disease, but only 30% considered that blood 
lipids played a major role. This result was taken as an 
indication that physicians needed more education. The true 
message of the survey was rather that evidence for choles- 
terol-lowering measures on a mass scale was not sufficient to 
convince the medical profession. The message for smoking 
and hypertension had, however, been well accepted. Let us 
review the main findings of the clinical trials on which the 
recommendations of the NHLBI were based. 
Lipid Intervention Trials 
The NHLBI supported two massive clinical trials to test 
the hypothesis that alterations in coronary heart disease risk 
factors would save lives. Both studies were well designed, 
well conducted and highly expensive. 
The Multiple Risk Factor Interventiodal Trial (MRFIT). 
This first trial was started in 1972. The final report (23), 
released in 1982, did not show any benefits from dietary 
control of blood cholesterol or other multiple risk factor 
interventions after approximately 7 years of follow-up. In 
fact, in the MRFIT study, morbidity and mortality were 
lower than had been expected in both the intervention and 
control groups. The estimated event rate for this study was 
based on Framingham data for middle-aged men at high risk 
for coronary heart disease. From a screened population of 
about 360,000 men, 12,866 were recruited for the study. This 
selection identified those who were both at high risk for 
coronary heart disease and who had an expressed willing- 
ness to participate in the study. One might assume that these 
individuals were particularly health conscious. The MRFIT 
study was conducted at a time when there already was a 
continuous and substantial reduction in mortality from cor- 
onary heart disease in the United States. This factor was to 
the benefit of all participants, causing less mortality than had 
been expected in both the intervention and control groups. 
The Framingham data, on which the calculation of sample 
size was based, were thereby invalidated. Furthermore, 
blood cholesterol was reduced by only 4% and the difference 
between the reduction in the intervention and control groups 
was only about 2%. Consequently, the results of MRFIT can 
hardly be used to support a nationwide blood cholesterol- 
reducing program. 
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The Lipid Research Clinic Coronary Primary Prevention 
Trials (LRC-CPPT). These trials were started in 1973. The 
aim was to study whether cholesterol-lowering dietary mea- 
sures plus administration of a cholesterol-lowering drug 
(cholestyramine) could reduce the incidence of coronary 
heart disease (24). These results (released in 1984) showed a 
lowering of coronary heart disease incidence but no differ- 
ence in total mortality between the two groups. 
In communicating the data to the public, some important 
facts seem to have been neglected. The LRC-CPPT was 
conducted in a highly selective group of 3,806 middle-aged 
men free of any signs of coronary heart disease. They all had 
a particularly high level and unfavorable pattern of blood 
cholesterol (~265 mgldl) and a low level of high density 
lipoprotein (HDL). In this selected group, the addition of 
cholestyramine to dietary measures resulted in a reduction in 
the risk for a fatal or nonfatal coronary event from 9.8% in 
the control group to 8.1% in the cholestyramine group, after 
7 years of study. Thus, the true difference between the 
groups was 1.7%. Calculating the percent reduction in the 
risk, this was reported as a 19% difference. Despite the lower 
coronary event rate, there was no difference in total mortal- 
ity between the two groups (control 3.7%, cholestyramine 
3.6%). 
Helsinki Heart Study. Although not available at the time 
of the aforementioned Consensus Conference and conse- 
quently not influencing the cholesterol awareness campaign, 
the recently published Helsinki Heart Study (25) is relevant 
to this discussion. This randomized, double-blind, placebo- 
controlled trial tested the effect of gemfibrozil, a drug that 
increases HDL cholesterol and lowers non-HDL choles- 
terol. The 4,081 participants were all middle-aged men 
without signs of coronary artery disease. They were selected 
from a screened population of 23,531 men with a non-HDL 
cholesterol level of 2200 mg/lOO ml (corresponding approx- 
imately to a total cholesterol level of 288 mg/lOO ml). After 5 
years of follow-up, cardiac end points (fatal and nonfatal 
myocardial infarction and sudden cardiac death) occurred in 
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2.7% of the 2,051 men who were randomized to gemfibrozil. 
For the 2,030 men receiving placebo, the corresponding 
figure was 4.1%, a difference in coronary events of 1.4% 
(p < 0.05) or, as the authors present it, a 34% reduction. 
Like the LRC-CPPT, the Helsinki Heart Study failed to 
show any difference in total mortality between active treat- 
ment and placebo groups. This rate was 2.2% in the gemfi- 
brozil compared with 2.1% in the placebo group. 
drugs have serious side effects. Furthermore, the curious 
relation between low plasma cholesterol and cancer is a 
dilemma (28-31). 
Will the Cholesterol Program 
Improve Longevity? 
Some answers to this question were recently published Therefore, it does not seem that the recent Finnish study 
adds important information to the question of whether a 
massive dietary program would reduce the risk of morbidity 
and mortality from coronary heart disease. The results were 
once more obtained from a highly select group of high risk 
men, by all means not representative of the general popula- 
tion The results were, furthermore, achieved not only by 
means of dietary modification but also through the inclusion 
of a highly potent cholesterol-lowering drug. To extrapolate 
the results of these studies to propose dietary interventions 
in the entire population is misleading at best and intellectu- 
ally dishonest at worst. 
The Most Recent Cholesterol 
Recommendations 
In October 1987 a special panel of health specialists met 
in Washington and staged a new media event (26). The aim 
was to urge physicians to monitor blood cholesterol in the 
entire adult American population every 5 years and pre- 
scribe diet and in some cases drugs for those with elevated 
lipid levels. Previously recommended standards for blood 
cholesterol levels were lowered even further. The customary 
250 mgldl level that was formerly considered the upper limit 
of normal was decreased to 200 mgldl. It was recommended 
to prescribe dietary measures and advice about annual blood 
cholesterol checks to patients with borderline to high levels 
(200 to 239 mg/dl). The panel claimed that government- 
sponsored campaigns were necessary because of the inept- 
ness or unwillingness of the medical profession to comply 
with given recommendations. This media campaign contin- 
ues without concern for criticism by the medical profession 
(8,2&22,27). 
Why do practitioners resist the new orders? Practitioners 
of medicine, research scientists and health planners are 
trained to use facts and scientific data derived from properly 
conducted laboratory, clinical and epidemiologic studies. 
They seem to object to the actions of these government 
committees and warn that the sudden hysteria may cause 
resentment by the public and medical profession. This, if it is 
allowed to occur, would undermine the very objective of 
primary prevention of coronary heart disease we all are 
trying to achieve. Basically, physicians and other members 
of the scientific community see little potential to increase 
longevity by means of the cholesterol awareness program. 
Some are concerned that almost all cholesterol-lowering 
(32). If a patient is at low risk and has practiced a lifelong 
program of cholesterol reduction similar to that proposed by 
the NCEP, the estimated life expectancy may be extended 
by three days to 12 months. For persons at high risk, life 
expectancy may be increased by 18 days to 12 months (32). 
Whelan and Olson (33) reported that, under the best of 
circumstances, of the anticipated 550,000 yearly coronary 
deaths in the United States only 6,000 might be prevented by 
adopting the new standards of cholesterol control. Oster and 
Epstein (34) reported that cost-effectiveness of the proposed 
program varies substantially, ranging from $36,000 to over 
$1 million per year of lives saved. Cost-effectiveness is 
higher for young patients, for those with additional coronary 
risk factors (for example, smoking or hypertension) and for 
those whose course of therapy is of less than lifelong 
duration. Conversely, it is lower for patients >55 years of 
age, for those with no additional coronary risk factors and 
for those treated during a lifetime. Pharmacologic therapy 
may not be cost-effective for all patients with an elevated 
cholesterol level, especially those >65 years of age. For 
younger patients, however, with additional coronary risk 
factors and more severe elevations in cholesterol level, the 
cost-effectiveness of therapy may be comparable with that of 
other accepted medical practices. 
Another view about cost-effectiveness and longevity was 
published by the Nobel Prize winners Brown and Goldstein 
(35), who stated: “If the LDL-receptor hypothesis is cor- 
rect, the human receptor system is designed to function in 
the presence of an exceedingly low LDL level. The kind of 
diet necessary to maintain such a level would be markedly 
different from the customary diet in Western industrial 
countries (and much more stringent than moderate low 
cholesterol diets of the kind recommended by the American 
Heart Association). It would call for total elimination of 
dairy products as well as eggs, and for a severely limited 
intake of meat and other sources of saturated fats. We 
believe such an extreme dietary change is not warranted for 
the entire population. There are several reasons. First, such 
a radical change in diet would have severe economic and 
social consequences. Second, it might well expose the 
population to other diseases now prevented by a moderate 
intake of fats. Third, experience shows most Americans will 
not adhere voluntarily to an extreme low-fat diet. Fourth, 
and most compelling, people vary genetically. Among those 
who consume the current high-fat diet of Western industrial 
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societies, only 50% will die of atherosclerosis; the other 50% 
are resistant to the disease.” 
How Accurate Are Lipid-Testing 
Measurements? 
Present lipid-testing methods are still unable to provide 
satisfactory evidence of significant repeatability and accu- 
racy. Several factors influence the test results (36,37). 
Among these are consumption of coffee, exercise habits and 
the use of medication. Intercurrent illness can also alter lipid 
levels. If a person is recumbent for 20 min before a sample is 
taken, there can be a 15% change in the cholesterol value. If 
the tourniquet is applied too tightly for >2 min, a change of 
2 to 10% in the value can result. In addition, the anticoagu- 
lant used in the vacuum container can dramatically affect the 
sample. Oxalate creates an 8% difference and citrate and 
fluoride can cause changes of as much as 12 and 18%, 
respectively. With regard to laboratory conditions, the mea- 
surement will be affected by the handling, storage and 
shipment of the specimen (38). Thus, it is important to make 
available a more reliable technique for blood cholesterol 
measurements before a nationwide campaign is started to 
lower cholesterol. It is hoped that this goal will be accom- 
plished in the near future. 
A Promising Clinical Intervention to Attempt 
to Arrest the Atherosclerotic Lesion 
The recent report by Blankenhorn et al. (39) on patients 
treated with coronary bypass grafts indicates that the use of 
nicotinic acid and colestipol decreased total blood choles- 
terol levels and reduced the size of arteriosclerotic lesions in 
the grafts. If verified by other investigators, this finding 
could be most important. We must, however, realize that 
restenosis of vein grafts might not be of the same arterio- 
sclerotic etiology as that in native arteries. In a recent review 
reporting a large coronary bypass series, it was stated that 
some of the customary coronary vein grafts restenosed 
within a few months. When the internal mammary arteries 
were used as the conduit, restenosis did not occur as 
frequently (40). So far no unequivocal relation has been 
found between coronary risk factors and late venous graft 
occlusion. Therefore, we must question whether there is a 
significant etiologic or technical difference between manage- 
ment of the obstructing lesion, which caused the restenosis 
of the vein graft, compared with that of the longer lasting 
internal mammary artery graft. Furthermore, observations 
from patients with already established and surgically treated 
coronary artery disease cannot be directly extrapolated to 
the general population or used as an argument for a gener- 
alized cholesterol-lowering program. 
Conclusions and Recommendations 
We believe that it is irresponsible to force the public into 
a costly cholesterol-reducing program without firm scientific 
evidence of the effectiveness of that intervention. Also we 
must let the public realize that, so far, we do not know all the 
answers to the question regarding the role of cholesterol 
reduction in primary prevention of atherosclerosis. At 
present it would be a major mistake to assume that coronary 
artery disease is primarily or exclusively caused by an 
elevated level of blood cholesterol. It would also be a major 
mistake to divert large economic resources into a project 
based on questionable assumptions and generalized extrap- 
olations of results from studies that were not designed to 
study the kind of interventions for which they now are used 
as support. 
Our concern seems to be shared with many others (8,16- 
18,20-22). The cholesterol awareness campaign addressed in 
an oversimplified way directly to the media and the general 
public has caused concern among many investigators. It may 
in particular divert resources from more meaningful future 
research studies of this multifactorial disease. Efforts must 
be directed toward further discovery of what may be even 
more important causative factors than the traditional risk 
factors-smoking, hypertension and high blood lipids. 
Among these are social networks, psychologic stress fac- 
tors, platelet-clotting dysfunction, regional factors acting on 
the arterial wall such as prostaglandins and other endo- 
crines, regional strain on the branching vessels and other 
factors. Further studies on the importance of certain lipo- 
protein subfractions are also needed. 
The cholesterol awareness campaign may have a tremen- 
dous impact on food manufacturing, processing and delivery 
systems, causing a change in direction ,of the nutrition 
industry that, if faulty, may be irreparable and affect the 
welfare of entire nations. Astonishingly, it seems that a small 
group of lipid hypothesis advocators have succeeded in 
persuading administrators to accept this very costly program 
without taking into consideration that from now on every 
expenditure in health care has to be well founded economi- 
cally and be reasonably cost-effective. 
What then are the reasons for this unusual development? 
Probably it is difficult for those who launched, conducted 
and interpreted large well designed lipid intervention studies 
to accept their inconclusive, sometimes negative, and in 
some aspects, actually discouraging results. To keep the 
illusion of a major break-through, sophisticated and con- 
firming statistics were applied in repeated attempts to fulfill 
prestudy hypothetical estimations of the importance and 
safety of a cholesterol-reducing program. Consequently, 
possible benefits of these diet/drug programs have been 
overemphasized and possible drawbacks may become un- 
tenable. Finally, and most seriously, the results obtained in 
extremely select groups of patients by very specific diet/drug 
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programs were considered conclusive for the outcome of 
cholesterol reduction in populations comprised of a mixture 
of young and old, men and women and consisting essentially 
of patients with moderate levels of plasma cholesterol. This 
is an unscientific approach that may cause the medical 
profession much harm and loss of respect in the future. 
We do not question the fact that a small number of 
patients with familial hypercholesterolemia may benefit from 
a strict cholesterol-reducing regimen that often includes 
drugs. Even in this group. however, the beneficial effect of 
these compounds must be weighed against the risks. Two 
large, independently controlled studies (24,25) documented 
an increased risk of violent death, which so far remains 
unexplained. The increased risk of gastrointestinal neo- 
plasms documented for clofibrate and discussed in relation 
to cholestyramine may be related to the drugs, but evidence 
is also accumulating that a cholesterol level that is too low 
for the individual may carry a risk by itself (I 1,24,28-3 I). No 
major study on lipid intervention has so far demonstrated a 
decrease in total mortality by the cholesterol-lowering inter- 
vention. These issues should be considered and explained to 
the individual who is about to commence a lifelong anticho- 
lesterol-reducing program and also to those who are to cover 
the costs. It is well recognized in medical history that 
individualized therapy always turns out to be the most 
comprehensible, yet reasonable approach. 
What then might the practitioner advise the public to do? 
We conclude that blood cholesterol should be checked on/y 
if there are sound clinical indications. The medical profes- 
sion should tell patients to abstain from tobacco smoking and 
to follow a reasonable blood pressure control program. A 
mixed diet low in calories and saturated fat should be 
recommended along with some physical exercise. This safe 
and economic advice does not necessitate the presently 
advocated dramatic cholesterol campaign of uncertain value 
but tremendous cost. 
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